MCi achieved 175% growth in new customers and $2.42B in contractor savings in 2024, driving efficiency across heavy industrial sectors.

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

Leqembi is already approved in the US, Japan, China, Great Britain and other markets ... and several other markets for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) ...

In a new study, researchers at the Federal University of Rio de Janeiro in Brazil found that computerized brain exercises ...

The Registry of Motor Vehicles is working to produce new specialty license plates promoting a message of “Overdose Awareness, ...

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...

It's been a historic week for snow in Kansas City and there are more snow chances ahead. Let's talk about the weather pattern ...

KANSAS CITY, Mo. — Another round of snowfall moved through the Kansas City region overnight, leaving additional snowfall ...

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...

DelveInsight's Mild Cognitive Impairment Market Insights report includes a comprehensive understanding of current treatment ...

As fires spread in neighborhoods across Los Angeles county, winter storms and weather are continuing to hit other parts of ...